It's not often you find a little biotech company plugging away at new cancer drugs in out-of-the-way places like Lawrence, KS. But that's just what Deciphera Pharmaceuticals has been doing.
Back in 2010, Ariad Pharmaceuticals' ridaforolimus was a promising cancer therapy worth up to $700 million in the eyes of Merck. Now, in light of an FDA rejection and some dimming development prospects, Merck has quietly washed its hands of the drug, handing it back to its former partner.
The French biotech announced this morning that it will collaborate with Paris-based Cellectis on UCART19, an engineered T cell with a chimeric antigen receptor for leukemia and lymphomas, as well as 5 other such programs. Servier is paying Cellectis $10 million down and up to $140 million per program in milestones in its gamble on the biotech's approach.
A new study out of Oregon State University has shown that a combination of mild heat and nanoparticle-delivered chemotherapy can have a whopping effect on ovarian cancer cells that have otherwise built up a resistance to cancer drugs.
Over the past two years Bayer has snagged an impressive string of key approvals for cancer and cardiovascular drugs--a much better record than many of its larger Big Pharma rivals. And today the pharma player is rolling out its slate of the next top drug prospects being groomed for late-stage pipeline work.
Almost lost in the din surrounding Merck's big about-face on the restructuring front yesterday, the pharma giant quietly posted some more promising early-stage data on what has become its brightest pipeline prospect: the cancer immunotherapy MK-3475.
ArQule watched its shares scrape the bottom last fall when it pulled the plug on a late-stage lung cancer drug, but rumors that the Woburn, MA, company is primed to release data that could revive tivantinib sent its stock price up as much as 19% on Friday.
A new method investigated by scientists at The Scripps Research Institute in La Jolla, CA, may pave the way for more effective chemotherapy drugs. Researchers have modified vinblastine, one of the most successful chemotherapy drugs of the past few decades, to make it more potent.
As genetic sequencing technology advances and scientists begin to unravel the underlying genetic factors in various types of cancer, it is now increasingly possible to find out why promising drugs have little or no effect in some patients and identify in which populations they have the most potential.
In a survey sponsored by the pharma industry, Americans revealed their biggest health concerns and desires for medical breakthroughs. The results come amid government budget squeezes to agencies such as the NIH and FDA that advocates say could stifle the delivery of innovative medicines to patients.